157 related articles for article (PubMed ID: 37580647)
21. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
23. Identification and verification of a 4-gene signature predicting the overall survival of cervical cancer.
Yuan L; Lu Z; Sun G; Cao D
Medicine (Baltimore); 2022 Oct; 101(42):e31299. PubMed ID: 36281082
[TBL] [Abstract][Full Text] [Related]
24. Establishment of three heterogeneous subtypes and a risk model of low-grade gliomas based on cell senescence-related genes.
Chen J; Wu L; Yang H; Zhang X; Xv S; Qian Q
Front Immunol; 2022; 13():982033. PubMed ID: 36052073
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of a novel cellular senescence-related lncRNA prognostic signature for predicting immunotherapy response in stomach adenocarcinoma.
Zeng C; Liu Y; He R; Lu X; Dai Y; Qi G; Liu J; Deng J; Lu W; Jin J; Liu Q
Front Genet; 2022; 13():935056. PubMed ID: 36092903
[No Abstract] [Full Text] [Related]
26. A senescence-based prognostic gene signature for colorectal cancer and identification of the role of SPP1-positive macrophages in tumor senescence.
Yu S; Chen M; Xu L; Mao E; Sun S
Front Immunol; 2023; 14():1175490. PubMed ID: 37090726
[TBL] [Abstract][Full Text] [Related]
27. The Role of High-Risk Human Papillomavirus-Related Long Non-Coding RNAs in the Prognosis of Cervical Squamous Cell Carcinoma.
Cheng Y; Yang S; Shen Y; Ding B; Wu W; Zhang Y; Liang G
DNA Cell Biol; 2020 Apr; 39(4):645-653. PubMed ID: 32045269
[TBL] [Abstract][Full Text] [Related]
28. The significance of m6A RNA methylation modification in prognosis and tumor microenvironment immune infiltration of cervical cancer.
Guo Y; Bai Y; Wang L; Xu Z; Wang X; Wang W
Medicine (Baltimore); 2022 Jul; 101(26):e29818. PubMed ID: 35777046
[TBL] [Abstract][Full Text] [Related]
29. An m1A/m6A/m5C-associated long non-coding RNA signature: Prognostic and immunotherapeutic insights into cervical cancer.
Pan C; Lin J; Dai X; Jiao L; Liu J; Lin A
J Gene Med; 2024 Jan; 26(1):e3618. PubMed ID: 37923390
[TBL] [Abstract][Full Text] [Related]
30. Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer.
Yu Z; Zhu Y; Ji J
Medicine (Baltimore); 2023 Jul; 102(28):e34287. PubMed ID: 37443486
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of a prognostic signature related to hypoxic tumor microenvironment in cervical cancer.
Nie C; Qin H; Zhang L
PLoS One; 2022; 17(6):e0269462. PubMed ID: 35657977
[TBL] [Abstract][Full Text] [Related]
32. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract][Full Text] [Related]
33. Research and experimental verification on the mechanisms of cellular senescence in triple-negative breast cancer.
Cao T; Huang M; Huang X; Tang T
PeerJ; 2024; 12():e16935. PubMed ID: 38435998
[TBL] [Abstract][Full Text] [Related]
34. Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer.
Liu B; Zhai J; Wang W; Liu T; Liu C; Zhu X; Wang Q; Tian W; Zhang F
Front Mol Biosci; 2022; 9():872932. PubMed ID: 35517856
[No Abstract] [Full Text] [Related]
35. Construction of a hypoxia-immune-related prognostic model and targeted therapeutic strategies for cervical cancer.
Xie S; Ding B; Wang S; Zhang X; Yan W; Xia Q; Meng D; Shen S; Yu B; Liu H; Hu J; Wang S
Int Immunol; 2022 Jul; 34(7):379-394. PubMed ID: 35561666
[TBL] [Abstract][Full Text] [Related]
36. Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.
Liu X; Zhou L; Gao M; Dong S; Hu Y; Hu C
Front Genet; 2022; 13():989646. PubMed ID: 36204323
[No Abstract] [Full Text] [Related]
37. Construction and experimental validation of a B cell senescence-related gene signature to evaluate prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Tan W
Funct Integr Genomics; 2022 Dec; 23(1):3. PubMed ID: 36527532
[TBL] [Abstract][Full Text] [Related]
38. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia.
Zhong F; Yang Y; Yao F; Liu J; Yu X; Wang XL; Huang B; Wang XZ
Aging (Albany NY); 2023 Oct; 15(20):11217-11226. PubMed ID: 37845004
[TBL] [Abstract][Full Text] [Related]
39. Genes associated with cellular senescence favor melanoma prognosis by stimulating immune responses in tumor microenvironment.
Liang X; Lin X; Lin Z; Lin W; Peng Z; Wei S
Comput Biol Med; 2023 May; 158():106850. PubMed ID: 37031510
[TBL] [Abstract][Full Text] [Related]
40. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
